Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | FGF1 | P05230 | 2/20 | 0.41 |
| ▸ | FGF2 | P09038 | 2/20 | 0.41 |
| ▸ | VEGFA | P15692 | 2/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.41 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20510986 | 0.97 | SIRT2 (0.43) | MMP13SIRT2BCHEACHEFGF1 | |
| SCHEMBL30891317 | 0.93 | SIRT2 (0.45) | MMP13SIRT2FGF1FGF2VEGFA | |
| SCHEMBL20511175 | 0.93 | SIRT2 (0.45) | MMP13SIRT2FGF1FGF2VEGFA | |
| SCHEMBL18132302 | 0.92 | CD209 (0.43) | SIRT2BCHEACHEFGF1FGF2 | |
| SCHEMBL16621007 | 0.92 | CD209 (0.43) | SIRT2BCHEACHEFGF1FGF2 | |
| SCHEMBL30392232 | 0.92 | SIRT2 (0.44) | MMP13SIRT2FGF1FGF2VEGFA | |
| SCHEMBL30391943 | 0.92 | SIRT2 (0.45) | MMP13SIRT2FGF1FGF2VEGFA | |
| SCHEMBL30891312 | 0.92 | MMP13 (0.46) | MMP13FGF1FGF2VEGFAHPSE | |
| SCHEMBL29880337 | 0.92 | MMP13 (0.46) | MMP13FGF1FGF2VEGFAHPSE | |
| SCHEMBL30891369 | 0.92 | MMP13 (0.46) | MMP13FGF1FGF2VEGFAHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | MMP13 1271/4885SIRT2 836/4885BCHE 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.